Switch-associated protein 70 antibodies in multiple sclerosis: Possible association with disease progression

Medical Principles and Practice

Volumn 23, Issue 3, 2014, Pages 239-245

  Türkoǧlu, Recai ^a   Gencer, Mehmet ^a   Ekmekçi, Duygu ^a   Ulusoy, Canan ^b   Erdaǧ, Ece ^b   Şehitoǧlu, Elçin ^b   Çavuş, Filiz ^b   Haytural, Hazal ^b   Küçükerden, Melike ^b   Yalçinkaya, Nazli ^b   Turan, Selin ^b   Akbaş Demir, Deniz ^a   Çoban, Arzu ^b   Vural, Burçak ^b   Tüzün, Erdem ^b  

^a HAYDARPASA NUMUNE EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Antibody; Chemokine; Multiple sclerosis; Relapse; Switch associated protein 70

Indexed keywords

CXCL13 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HEAT SHOCK PROTEIN 70; HUMORAL ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN ANTIBODY; RANTES; SWITCH ASSOCIATED PROTEIN 70 ANTIBODY; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4; BETA INTERFERON; BIOLOGICAL MARKER; FINGOLIMOD; GLATIRAMER; METHYLPREDNISOLONE; NATALIZUMAB; CYTOKINE; DNA BINDING PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; IMMUNOGLOBULIN G; NUCLEAR PROTEIN; SWAP70 PROTEIN, HUMAN;

ADULT; ARTICLE; CELL LYSATE; CLINICAL ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNOBLOTTING; MALE; MULTIPLE SCLEROSIS; NUCLEOTIDE SEQUENCE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN MACROARRAY; RELAPSE; REMISSION; SCORING SYSTEM; CLINICAL FEATURE; CORRELATION ANALYSIS; PHYSICAL DISABILITY; PROGNOSIS; PROTEIN EXPRESSION; IMMUNOLOGY; MIDDLE AGED;

ADULT; BIOLOGICAL MARKERS; CYTOKINES; DISEASE PROGRESSION; DNA-BINDING PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NUCLEAR PROTEINS;

EID: 84901605117     PISSN: 10117571     EISSN: 14230151     Source Type: Journal    
DOI: 10.1159/000358221     Document Type: Article

References (22)

1. Meinl E, Krumbholz M, Hohlfeld R: B lineage cells in the inflammatory central nervous system environment: Migration, maintenance, local antibody production, and therapeutic modulation. Ann Neurol 2006; 59: 880-892.
2. Becher B, Segal BM: T(H)17 cytokines in autoimmune neuro-inflammation. Curr Opin Immunol 2011; 23: 707-712.
3. Erda E, Tüzün E, Uurel E, et al: Switch-associated protein 70 antibodies in multiple sclerosis: Relationship between increased serum levels and clinical relapse. Inflamm Res 2012; 61: 927-930.
4. Bahaie NS, Hosseinkhani MR, Ge XN, et al: Regulation of eosinophil trafficking by SWAP-70 and its role in allergic airway inflammation. J Immunol 2012; 188: 1479-1490.
5. Pearce G, Angeli V, Randolph GJ, et al: Signaling protein SWAP-70 is required for efficient B cell homing to lymphoid organs. Nat Immunol 2006; 7: 827-834.
6. Sivalenka RR, Jessberger R: SWAP-70 regulates c-kit-induced mast cell activation, cellcell adhesion, and migration. Mol Cell Biol 2004; 24: 10277-10288.
7. Pigard N, Elovaara I, Kuusisto H, et al: Therapeutic activities of intravenous immunoglobulins in multiple sclerosis involve modulation of chemokine expression. J Neuroimmunol 2009; 209: 114-120.
8. Szczuciski A, Losy J: CCL5, CXCL10 and CXCL11 chemokines in patients with active and stable relapsing-remitting multiple sclerosis. Neuroimmunomodulation 2011; 18: 67-72.
9. Baraczka K, Nékám K, Pozsonyi T, et al: Concentration of soluble adhesion molecules (sVCAM-1, sICAM-1 and sL-selectin) in the cerebrospinal fluid and serum of patients with multiple sclerosis and systemic lupus erythematosus with central nervous involvement. Neuroimmunomodulation 2001; 9: 49-54.
10. Alter A, Duddy M, Hebert S, et al: Determinants of human B cell migration across brain endothelial cells. J Immunol 2003; 170: 4497-4505.
11. Tachimoto H, Ebisawa M: Effect of interleukin-or tumor necrosis factor-alpha on eosinophil adhesion to endothelial cells under physiological flow conditions. Int Arch Allergy Immunol 2007; 143: 33-37.
12. Rossi S, Mancino R, Bergami A, et al: Potential role of IL-13 in neuroprotection and cortical excitability regulation in multiple sclerosis. Mult Scler 2011; 17: 1301-1312.
13. Kalinowska-yszczarz A, Szczuciski A, Pawlak MA, et al: Clinical study on CXCL13, CCL17, CCL20 and IL-17 as immune cell migration navigators in relapsing-remitting multiple sclerosis patients. J Neurol Sci 2011; 300: 81-85.
14. Polman CH, Reingold SC, Edan G, et al: Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald Criteria'. Ann Neurol 2005; 58: 840-846.
15. Vural B, Demirkan A, Ugurel E, et al: Seroreactivity against PTEN-induced putative kinase. (PINK1) in Turkish patients with Beḩet's disease. Clin Exp Rheumatol 2009; 27:S67-S72.
16. Vural B, Uurel E, Tüzün E, et al: Anti-neuronal and stress-induced-phosphoprotein 1 antibodies in neuro-Beḩet's disease. J Neuroimmunol 2011; 239: 91-97.
17. Akhter E, Burlingame RW, Seaman AL, et al: Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus 2011; 20: 1267-1274.
18. Tüzün E, Saini SS, Ghosh S, et al: Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Neuromuscul Disord 2006; 16: 137-143.
19. Ocaña-Morgner C, Reichardt P, Chopin M, et al: Sphingosine 1-phosphate-induced motility and endocytosis of dendritic cells is regulated by SWAP-70 through RhoA. J Immunol 2011; 186: 5345-5355.
20. Groves A, Kihara Y, Chun J: Fingolimod: direct CNS effects of sphingosine 1-phosphate (S1P) receptor modulation and implications in multiple sclerosis therapy. J Neurol Sci 2013; 328: 9-18.
21. Huu DL, Matsushita T, Jin G, et al: FTY720 ameliorates murine sclerodermatous chronic graft-versus-host disease by promoting expansion of splenic regulatory cells and inhibiting immune cell infiltration into skin. Arthritis Rheum 2013; 65: 1624-1635.
22. Nofer JR, Bot M, Brodde M, et al: FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007; 115: 501-508.